AOSSM 2022 Annual Meeting Recordings - no CME-The Business of OrthoBiologics in Clinical Practice

Video Transcription

Video Summary

In this video, the speaker discusses the cost and effectiveness of orthobiologic treatments, such as PRP and cell therapy. They highlight that these treatments are generally not covered by commercial insurance and their effectiveness is still debatable. Despite this, patients are drawn to these treatments due to aggressive marketing and the promise of cutting-edge therapies. The speaker emphasizes the need for patients to be informed about the high out-of-pocket costs and the variability and unpredictability of outcomes. They mention that PRP is not covered by insurance and provide information about the cost and billing process. The speaker also discusses studies on the cost-effectiveness of PRP, comparing it to other treatment options like steroids and HA. They conclude that PRP can be cost-effective from the payer perspective with the right pricing and delay in knee arthroplasty. The speaker also mentions studies on the cost and use of cell therapy, highlighting the codes and expenses associated with the procedures. They emphasize the need for further research and rigorous studies in this field and the importance of responsible use and avoiding indiscriminate use of these therapies.

Asset Caption

Scott Rodeo, MD

Keywords

orthobiologic treatments

PRP

cell therapy

cost and effectiveness

commercial insurance